INOVIO initiated phase 1 clinical trial of its COVID-19 vaccine and plans first dose
On Apr. 6, 2020, Inovio Pharma announced the FDA has accepted the company’s Investigational New Drug application for INO-4800, its DNA vaccine candidate designed to prevent COVID-19 infection, paving the way for Phase 1 clinical testing of INO-4800 in healthy volunteers beginning this week. The first dosing has begun.
Tags:
Source: Inovio Pharmaceuticals Inc.
Credit: